Pharmacological effects of 1,3-dimethyl-5-aminoadamantane, a new adamantane derivative.
D000547:Amantadine / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects; D001923:Brain Chemistry / Q000187:drug effects; D002375:Catalepsy / Q000139:chemically induced / Q000188:drug therapy; D002746:Chlorpromazine / Q000494:pharmacology; D003913:Dextroamphetamine / Q000494:pharmacology; D004220:Disulfides / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism; D005260:Female; D005476:Fluphenazine / Q000494:pharmacology; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D008297:Male; D008781:Methyltyrosines / Q000494:pharmacology; D009043:Motor Activity / Q000187:drug effects; D009638:Norepinephrine / Q000378:metabolism; D010095:Oxotremorine / Q000494:pharmacology; D010276:Parasympatholytics / Q000494:pharmacology; D051381:Rats; D012018:Reflex / Q000187:drug effects; D012110:Reserpine / Q000494:pharmacology; D013141:Spiro Compounds / Q000494:pharmacology; D013239:Stereotyped Behavior / Q000187:drug effects
D004220:Disulfides; D007093:Imidazoles; D008781:Methyltyrosines; D010276:Parasympatholytics; D013141:Spiro Compounds; D010095:Oxotremorine; D012110:Reserpine; D000547:Amantadine; D006220:Haloperidol; D001058:Apomorphine; D005476:Fluphenazine; D003913:Dextroamphetamine; D002746:Chlorpromazine; D004298:Dopamine; D009638:Norepinephrine